Prelude Therapeutics, Inc. (PRLD)

Over the past six months, Prelude Therapeutics' stock price has been impacted by several events. On November 4, 2025, a strategic business update led to a 55.78% stock price decrease. On November 12, 2025, the company reported its Third Quarter 2025 financial results, resulting in an 8.89% stock price increase. On December 6, 2025, data from MPN programs was presented at the 2025 ASH Annual Meeting, with no immediate stock price change. On February 3, 2026, FDA clearance of an IND for PRT12396 caused a 12.81% stock surge. On March 10, 2026, the company reported its Full Year 2025 Financial Results, leading to a 16.50% stock price increase. On March 17, 2026, acceptance of a preclinical abstract for PRT13722 at the 2026 AACR Annual Meeting resulted in a 9.04% stock price decrease. On March 28, 2026, Prelude Therapeutics' price target was increased by 29.17% to $5.27.

As a clinical-stage precision oncology company, Prelude Therapeutics' products are in development and not yet commercialized. Therefore, demand seasonality is not applicable, as the company focuses on research, development, and clinical trials rather than commercial sales.

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies for genetically defined oncology targets. The company operates in the Pharmaceutical Products industry, utilizing a chemical biology approach to create targeted treatments. Its pipeline includes PRT2527, a PI3K-alpha/delta inhibitor; PRT543, a PRMT5 inhibitor; PRT13722, an oral KAT6A selective degrader; PRT12396, a mutant-selective JAK2V617F inhibitor; a highly selective KAT6A oral degrader program; mutant selective JAK2V617F JH2 inhibitors; and Degrader Antibody Conjugates (DACs).

Prelude Therapeutics, Inc. is headquartered in Wilmington, Delaware, USA. The company aims to deliver precision medicines to individuals with hard-to-treat and treatment-resistant malignancies worldwide.

Prelude Therapeutics is known as a precision oncology company focused on developing innovative medicines for cancer patients with high unmet medical needs. The company emphasizes a scientific approach to drug discovery and development, aiming to translate scientific insights into effective treatments. Its communications highlight expertise in targeted protein degradation and commitment to advancing a diverse pipeline of precision oncology assets. There is no specific information available detailing events that have negatively impacted Prelude Therapeutics' brand reputation in the past year, beyond the general stock price fluctuations.

Prelude Therapeutics Incorporated has 50 institutional owners and shareholders holding a total of 28,458,039 shares. Major institutional owners include Orbimed Advisors Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, Kynam Capital Management, LP, Two Sigma Investments, Lp, Price T Rowe Associates Inc /md/, Acadian Asset Management Llc, Morgan Stanley, Marshall Wace, Llp, and Geode Capital Management, Llc. Other notable holders include Goldman Sachs Group Inc., Sphera Funds Management LTD, Jacobs Levy Equity Management Inc., and JPMorgan Chase & Co.